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Abstract
Background: The population of adult patients with early-treated phenylketonuria (PKU) following newborn
screening is growing substantially. The ideal target range of blood phenylalanine (Phe) levels in adults outside
pregnancy is a matter of debate. Therefore, prospective intervention studies are needed to evaluate the effects of
an elevated Phe concentration on cognition and structural, functional, and neurometabolic parameters of the brain.
Methods: The PICO (Phenylalanine and Its Impact on Cognition) Study evaluates the effect of a 4-week Phe load
on cognition and cerebral parameters in adults with early-treated PKU in a double-blind, randomized, placebo-
controlled, crossover, noninferiority trial.
Participants: Thirty adult patients with early-treated PKU and 30 healthy controls comparable to patients with
regard to age, sex, and educational level will be recruited from the University Hospitals Bern and Zurich,
Switzerland. Patients are eligible for the study if they are 18 years of age or older and had PKU diagnosed after a
positive newborn screening and were treated with a Phe-restricted diet starting within the first 30 days of life.
Intervention: The cross-over intervention consists of 4-week oral Phe or placebo administration in patients with PKU.
The study design mimics a Phe-restricted and a Phe-unrestricted diet using a double-blinded, placebo-controlled
approach.
Objectives: The primary objective of the PICO Study is to prospectively assess whether a temporarily elevated Phe
level influences cognitive performance (working memory assessed with a n-back task) in adults with early-treated
PKU. As a secondary objective, the PICO Study will elucidate the cerebral (fMRI, neural activation during a n-back
task; rsfMRI, functional connectivity at rest; DTI, white matter integrity; and ASL, cerebral blood flow) and
neurometabolic mechanisms (cerebral Phe level) that accompany changes in Phe concentration. Cognition, and
structural and functional parameters of the brain of adult patients with early-treated PKU will be cross-sectionally
compared to healthy controls. All assessments will take place at the University Hospital Bern, Switzerland.
(Continued on next page)
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Randomization: Central randomization will be used to assign participants to the different treatment arms with age,
sex, and center serving as the stratification factors. Randomization lists will be generated by an independent
statistician.
Blinding: All trial personnel other than the statistician generating the randomization list and the personnel at the
facility preparing the interventional product are blinded to the assigned treatment.
Discussion: Using a combination of neuropsychological and neuroimaging data, the PICO Study will considerably
contribute to improve the currently insufficient level of evidence on how adult patients with early-treated PKU
should be managed.
Trial registration: The study is registered at clinicaltrials.gov (NCT03788343) on the 27th of December 2018, at
kofam.ch (SNCTP000003117) on the 17th of December 2018, and on the International Clinical Trials Registry
Platform of the WHO.
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Background
Phenylketonuria (PKU) is a rare autosomal recessive dis-
order caused by a defective function of the phenylalanine
hydroxylase enzyme leading to an impaired conversion of
the amino acid phenylalanine (Phe) to tyrosine. Untreated
PKU with increased Phe concentrations in the blood and
brain during childhood leads to severe irreversible neuro-
logical impairment with, e.g., mental retardation, intellec-
tual disability, behavioral problems, or other neurological
sequelae such as epilepsy or movement disorders [1]. New-
born screening for PKU was established around 1965, en-
abling early treatment with a dietary restriction of Phe (low
protein diet) and Phe-free protein substitutes (amino acid
mixtures) soon after birth. Consequently, the population of
adults with phenylketonuria with an absence of neuro-
logical disabilities has grown substantially since the early
1980s [1]. Most of these early-treated adult patients live a
“normal” life as shown in an earlier study at our center, in
which 15% of the adult patients with PKU went to high
school or graduated from university [2].
Despite wide agreement on the treatment strategy and tar-
get Phe concentrations in childhood and for women during
pregnancy, no consensus on safe Phe concentrations in
adulthood has been reached so far [3]. Traditionally, the low
protein diet had been enforced only during childhood and
adolescence, leaving adult patients with PKU “off-diet.”
Nonetheless, concerns remain that high phenylalanine levels
may still have negative effects in adolescents and adults with
PKU [4, 5]. Limited evidence of irreversible neurological
damage exists, but over the last decade, observational and
cross-sectional studies associated high Phe in early-treated
adult patients with cognitive problems [6–8], psychiatric
symptoms, and behavioral abnormalities [4–6, 9–13].
The executive deficit hypothesis of PKU suggests that se-
lective impairments of executive functions may result from
abnormalities of neurotransmitters, in particular dopamine,
a neurochemical that is critical for prefrontal cortical func-
tions [7]. Coming along with alterations of prefrontal
cortex functions is a slight decrease in intelligence ob-
served in patients with PKU [14]. Decreased intelligence is
linked with impairments in higher-order cognitive func-
tions, including executive functions [15] and attention [16].
In particular, various studies have reported impaired work-
ing memory performance in patients with PKU [5, 11].
Working memory is an executive function that encom-
passes the ability of maintaining information during a short
period of time, as well as manipulating and refreshing this
information to successfully complete a task [17]. Hence,
working memory is crucial in everyday life; for example, it
helps with focus on a demanding task or following a se-
quence of actions [18]. Also, other subtypes of executive
functions have been reported to be affected from PKU,
such as inhibition and cognitive flexibility [15]. Most of the
previous studies described above, however, have focused
on selected cognitive domains resulting in a lack of a com-
prehensive overview across cognitive domains. Such an
overview is crucial to increase knowledge about the extent
to which cognition is affected by PKU. More importantly,
it enables a thorough evaluation of PKU treatment success.
The neurotoxicity of Phe during childhood and adoles-
cence is additionally apparent in regard to structural and
functional characteristics of the brain [19, 20]. In detail, an
estimated 90% of patients with early-treated PKU display
periventricular white matter lesions and reduced white mat-
ter integrity, which likely impede processing speed, often re-
ported to be reduced in patients with PKU [21, 22]. In
contrast, little is known about gray matter changes in PKU.
Pérez-Dueñas and colleagues (2006) found volumetric re-
ductions in gray matter structures including the motor cor-
tex and thalamus [23]. However, data were acquired from a
mixed sample of early- and late-treated patients, restricting
the interpretation of findings. Smaller whole brain volume
and smaller parietal and occipital cortex but larger volume
of the putamen were described in early-treated patients with
PKU [9, 19]. The latter study included patients 9–33 years
old, limiting the generalizability of results due to the lack of
Trepp et al. Trials          (2020) 21:178 Page 2 of 11
comparability between the cognitive and neuroimaging data
of children and adults. In regard to functional brain net-
works, atypical brain activation during a working memory
task [24, 25] and decreased functional connectivity [10] have
been described, likely coming along with cognitive alter-
ations of this vulnerable patient sample. Patients with
PKU additionally display neurometabolic alterations in
upfield and downfield spectra, such as a decrease in cho-
line concentration [20] and an increase in cerebral Phe
level [26], respectively. Due to the limited amount of neu-
roimaging studies, still much uncertainty exists about the
relationship between Phe concentrations and brain
abnormalities in adult patients. Importantly, these
studies are unable to distinguish between past effects
of elevated Phe levels on the brain during childhood
and adolescence and a potentially ongoing negative
impact in adulthood. Previous intervention studies
were mostly open label, associating the level of Phe
intake in the diet with cognitive performance [27].
However, the perception of one’s own compliance
with dietary recommendations may influence cognitive
performance. One small intervention trial investigated
the effect of the Phe concentration on cognition in a
prospective randomized, placebo-controlled, double-
blinded way [28]. Ten Hoedt and colleagues suggested
a negative effect of high plasma Phe levels on sus-
tained attention and on mood in nine adult patients
with PKU, concluding that “a Phe restricted ‘diet for
life’ might be an advisable option for many” [28].
Due to the availability of only low-grade evidence, rec-
ommendations of national and international guidelines
differ substantially with regard to Phe target levels in
adult patients with PKU [3, 29]. The most recent Euro-
pean guidelines suggest keeping Phe concentrations
below 600 umol/l throughout adulthood, while stating
this is a grade D recommendation. Consequently, not
only are the recommendations unequally accepted by
the treating metabolic specialists, but more than 50% of
adults with PKU exhibit substantial difficulty in main-
taining the compliance necessary to reach the recom-
mended target Phe concentrations [30, 31]. Therefore,
prospective intervention studies in adult patients with
PKU are needed to evaluate the effects of dietary restric-
tions on cognition, cerebral and neurometabolic parame-
ters, and quality of life.
Objectives
The primary objective is to prospectively assess the im-
pact of higher Phe load on cognitive performance in
adults with early-treated PKU. Secondarily, the study
aims to elucidate the functional and neurometabolic
mechanism in the brain accompanying changes in Phe
concentration.
Methods/design
Design
The PICO Study is a prospective, single-center, double-
blinded, randomized, placebo-controlled, crossover, non-
inferiority study. In total, 30 adult patients with PKU will
be included in the study. Patients with PKU will cross-
over, thereby serving as their own controls. To prevent
the occurrence of carryover effects, a washout period of
4 weeks will be implemented in between the treatment
arms (see Fig. 1). To cross-sectionally compare cognitive
and neuroimaging data, 30 healthy controls will serve as
a reference group.
This study protocol is written according to the SPIRIT
2013 Statement [32] providing evidence-based recom-
mendations for the minimum content of a clinical trial
protocol. SPIRIT is widely endorsed as an international
standard for trial protocols. A SPIRIT Table is presented
below (Table 1, Additional file 1).
Recruitment
Patients will be recruited from the treating metabolic spe-
cialist at the adult metabolic center of the University Hos-
pital Bern and Zurich, Switzerland. Patients will be
screened by the metabolic specialist either on the phone or
in the course of one of their regular metabolic consultations
(T0). Patients overseen at metabolic centers other than the
study site will first be informed about the study by their
treating metabolic specialist. If the patient is interested in
the study participation, the local treating metabolic special-
ists informs the study physician (R.T.) who will invite the
patient to the study center at the University Hospital Bern
on condition that they fulfill the eligibility criteria.
Patients will be asked whether family members or friends
are interested in participating in the study as control par-
ticipants. Healthy controls will be additionally recruited
through advertisements placed at websites, by word-of-
mouth, and with flyers in the area of Bern.
Interested potential participants will be informed
about the study by means of an information brochure
and written informed consent will be obtained after the
participants have had enough time to consider the infor-
mation and to ask any questions.
Participants
Thirty adult patients with early-treated PKU and 30
healthy controls comparable to patients with regard to age,
sex, and educational level will be recruited. To achieve
comparable groups, patients will be assessed first while
consecutively searching for controls that are comparable in
their demographics. Patients are eligible for the study if
they are 18 years of age or older and have PKU diagnosed
after a positive newborn screening and treated with Phe-
restricted diet starting within the first 30 days of life.
Trepp et al. Trials          (2020) 21:178 Page 3 of 11
Patients will be excluded if they did not follow a
Phe-restricted diet within 6 months before the study,
exhibited Phe concentrations above 1600 μmol/L
within 6 months before the study, or have a concomi-
tant disease status that could significantly affect pri-
mary or secondary outcomes (e.g., untreated vitamin
B12 deficiency).
Female patients of childbearing potential will be ex-
cluded if they are not using or not willing to continue
using at least one highly efficient method of contracep-
tion (Pearl index less than 1) for the entire study dur-
ation, are pregnant or intend to become pregnant during
the course of the study, or are breast feeding.
Patients and healthy controls will be excluded if they
have known or suspected noncompliance; show drug or
alcohol abuse; changed medications likely to significantly
interfere with cognitive functions; have known or sus-
pected hypersensitivity or allergy to one of the ingredi-
ents of the placebo; are unable to follow the procedures
of the study, e.g., due to language problems (lack of flu-
ency in German or French); participated in another
intervention study within the 30 days preceding and dur-
ing the present study; or have a condition that interferes
with the acquisition of MRI scans.
Intervention
The intervention, consisting of a 4-week oral administra-
tion of Phe or placebo in patients with PKU, is initiated to
simulate a controlled, temporary discontinuation of their
diet. To ensure the blinded setting and avoid changing the
usual low protein diet of the patients, Phe or placebo will
be administered in the form of capsules. In other words,
this mimics a Phe-restricted and a Phe-unrestricted diet
using a double-blinded, placebo-controlled approach. Pa-
tients will be randomly assigned to one of two treatment
groups starting either with Phe-containing capsules or with
placebo-containing capsules. After 4 weeks, patients cross
over to the alternative treatment arm. All patients and
study investigators will be blinded to the treatment assign-
ment until the completion of the study.
The investigational product (IP) consists of capsules
containing 250 mg Phe and placebo capsules indistin-
guishable from Phe capsules and will be supplied by
the Laboratorium Dr. G. Bichsel AG, 3800 Unterseen,
Switzerland, according to applicable regulations. The
amino acid Phe is part of the normal dietary protein
and marketed as a dietary supplement, although not
designated for this patient group. Using a similar ap-
proach as ten Hoedt [28], the amount of Phe (and
placebo) given will be adapted according to sex and
body weight with the aim to mimic the total Phe in-
take likely to be consumed by a healthy adult of the
same sex and weight or by the patient with PKU be-
ing fully “off-diet.” Taking into account that the usual
daily protein intake in adults in Switzerland is ap-
proximately 0.9–1.2 g per kilogram of body weight
[33], that the average protein intake is somewhat
higher in men than in women, that within a normal
diet the portion of Phe of the protein content is ap-
proximately 5%, and that adult patients with mild to
classical PKU mostly consume approximately 40% of
the usual protein intake, the following additional
doses of Phe to be administered were calculated:
 Female < 60 kg: 1500 mg per day (divided into three
doses: 250 mg 2–2–2–0), ≥60 kg: 2000 mg per day
(divided into three doses: 250 mg 2–2–4–0)
 Male < 60 kg: 2500 mg per day (divided into three
doses: 250 mg 4–2–4–0), ≥60 kg: 3000 mg per day
(divided into three doses: 250 mg 4–4–4–0)
Fig. 1 Study flow chart. Legend. T0 = screening; T1 = first assessment; T2 = second assessment; T3 = third assessment; T4 = fourth and
last assessment
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Assignment to individual doses will be done at the first
screening (T0). The assigned dose of the IP will be kept
throughout the whole study, and weight fluctuations will
not be considered. The capsules can be ingested before,
during, or after a meal or together with the usual amino
acid supplements. The last capsule of the given interven-
tion period will be timed to be ingested with the last meal
before the study visit.
To prevent the occurrence of carryover effects, a wash-
out period of 4 weeks has been incorporated into the study
design and will be implemented in between the two treat-
ment phases (see Fig. 1). The bioavailability of Phe is close
to 100% [34]. Phe blood concentrations are known to de-
crease within 1 to 2 weeks after Phe intake reduction in
Phe tolerance reassessment [35]. The 4-week washout
period is equivalent to 12 times the length of the estimated
half-life of Phe concentration in the blood of patients, with
0% residual phenylalanine hydroxylase activity [36].
Patients will be asked to maintain their usual protein-
restricted diet and amino acid supplements throughout
the whole study period. In addition, patients will provide
a dietary protocol during the last 3 days before the first
(T1) assessment. They will be instructed to replicate the
diet of the 3 days before T1 as closely as possible during
the 3 days before T2, T3, and T4.
Healthy controls will not receive any intervention but
will undergo the same cognitive assessment and neuro-
imaging measurements as patients at T1 except for
Table 1 Schedule of enrolment, interventions, and assessment (according to the SPIRIT guidelines)
T0 = Recruitment, Informed Consent, Randomization; T1 = before the first treatment arm (neuropsychology, neuroimaging and blood sample assessment); T2 =
after the first treatment arm (neuropsychology, neuroimaging and blood sample assessment); T3 = after the wash-out period and before the second treatment
arm (neuropsychology, neuroimaging and blood sample assessment); T4 = after the second treatment arm (neuropsychology, neuroimaging and blood sample
assessment); IP Investigational product
*additional weekly phone-calls to assess adverse events
1Working memory, inhibition, cognitive flexibility, neural activation during working memory fMRI
2IQ, memory, fine motor speed, attention
3Voxel-based morphometry, diffusion tensor imaging, resting-state functional imaging, arterial spin labeling, magnetic resonance spectroscopy
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blood and dry blood sampling. Healthy controls will only
be assessed once (T1).
Randomization
Computer-generated central randomization will be used to
assign participants to the different treatment arms. To ensure
comparability of treatment groups, the age (less than 30 years
old, more than 31 years old), sex, and center (Zurich, Bern)
will serve as the stratification factors. Randomization lists will
be generated by an independent statistician at the Clinical
Trial Unit (CTU) Bern. The randomization list will be trans-
ferred to the Laboratorium Dr. G. Bichsel AG by the inde-
pendent statistician. Randomization is performed at the
study site (University Hospital of Bern) by the study coordin-
ator (S.A.), who will inform the Laboratorium about the
randomization result and who will add those patient charac-
teristics (weight, sex) that influence the IP dosage. All trial
personnel other than the statistician generating the list and
the personnel at the facility preparing the IP packs are
blinded to the assigned treatment. In case of a severe adverse
event, the treating metabolic specialist (M.H.) will first be un-
blinded, enabling the treatment and care of the affected
patient.
Procedure
All study visits and procedures will be performed at the
study site, Inselspital, Bern University Hospital, Switzerland.
In patients, cognitive performance as well as structural,
functional, and neurometabolic parameters of the brain will
be measured at four time points, one baseline measurement
before each and one measurement after each treatment
phase (see Fig. 1).
T1, T2, T3, and T4 will be carried out at the University
Hospital Bern and will last approximately 5 hours (including
breaks and breakfast). Each time point consists of a preg-
nancy test, fasting blood sample (amino acid profile), neuro-
imaging, cognitive assessment, physical examination, and
assessment of adverse events. Cognitive assessment could be
affected by drawing attention to negative influences immedi-
ately beforehand. Therefore, physical examination and as-
sessment of symptoms and adverse effects will be placed at
the end of each study visit after completion of neuroimaging
and cognitive assessment.
The visits will take place in the morning. Before T2 and
T4, the last IP will be taken together with the last meal,
which will be placed to approach an antecedent fasting
period of 10 h (range 8–12 h) before the assessment. For a
given patient, T2, T3 and T4 will be scheduled for the
same time of the day as the assessment at T1 to keep the
length of the antecedent fasting period consistent.
Neuropsychology
Each of the four neuropsychological assessments (T1 to
T4) will include evaluations of executive functions, namely
working memory (n-back task; Test of Attentional Per-
formance, TAP [37]; Letter-Number-Sequencing; Wechs-
ler Adult Intelligence Scale Fourth Edition, WAIS-IV
[38]), inhibition, cognitive flexibility and fluency (Color-
Word Interference Test; Delis-Kaplan Executive Function
System, D-KEFS [39]). Further, attention (Alertness, Sus-
tained Attention, Divided Attention; TAP [37]), verbal
and design fluency (D-KEFS [39]), and fine motor control
(Purdue Pegboard [40]) will be assessed.
Psychological questionnaires will be used to assess mood
(short form of the Profile of Mood States; POMS [41]), de-
pressive symptoms (Beck’s Depression Inventory; BDI-II
[42]) and health-related quality of life (PKU quality of life;
PKUQOL [43]). The first neuropsychological assessment
will additionally contain the assessment of general intellec-
tual performance (short-form of WAIS-IV [38]).
Neuroimaging
Structural imaging Anatomical MRI will be used to de-
termine structural characteristics of the brain. All MRI
images will be acquired using a 3.0 Tesla Siemens Mag-
netom Prisma, (Siemens Erlangen, Germany), equipped
with a 64-channel head coil. Anatomical imaging will be
performed using a 3-D T1 magnetization prepared rapid
gradient echo (MPRAGE) sequence for acquisition of
T1-weighted structural brain imaging (acquisition time
TA: 4:34 min, repetition time TR = 1950ms, echo time
TE = 2.26 ms, slices per slap 176, field of view FoV 256
mm, 1 mm voxel resolution).
Functional imaging Resting state fMRI (rs-fMRI) will
be performed to obtain information about regional inter-
actions (functional connectivity) between and within
brain regions at rest. For the investigation of rs-fMRI, a
multi-band EPI sequence from the University of Minne-
sota (Center for Magnetic Resonance Research), TA: 6:
39 min, and flip angle 52° (avoiding rf-clipping; is in the
order of the Ernst angle for TR = 1300 ms and T1 of gray
matter) will be used.
Functional MRI (fMRI) of working memory will be assessed
to observe the influence of Phe on the characteristics of this
higher-level cognitive network. fMRI will be administered
using an established paradigm assessing the visuospatial
working memory network (TA = 9.52 min, TR = 1000 ms,
voxel size = 2 x 2 x 2, 48 slices, slice thickness 2 mm).
Diffusion tensor imaging (DTI) will be performed to
measure the integrity of white matter tracts using a
Double-SE weighted q-space sequence [44] with 124 di-
rections, slice and PE acceleration 2 and 2 resp., voxel
size 2.2 mm iso, slices 56, and TA: 7:55 min.
Three-dimensional arterial spin labeling (3D-ASL) will
be applied to assess cerebral blood flow. An QII FAIR 3D-
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ASL will be administered (TA, 4:59min; PM, REF; Voxel
size, 1.5 × 1.5 × 3.0mm; slices per slab 40; TR = 4600ms;
TE = 16.18ms; post-labeling (inversion time) varies de-
pending on patient and age; bolus duration 800ms; and in-
version time 1500-2000ms). For quantification purpose of
arterial blood flow, an M0 run is added.
Magnetic resonance spectroscopy (MRS) will be
utilized to capture potential alterations of brain Phe
concentrations. Data will be acquired with a semi-LASER
sequence [45, 46].
All MR scans will be subjected to a radiological evalu-
ation by an experienced neuroradiologist.
To minimize head motion, a head support system con-
sisting of two pillows positioned on each side of the head
will be used. Earplugs will reduce the scanner noise.
Primary outcome and hypothesis
The main hypothesis is that in adult patients with early-
treated PKU, a 4-week period of Phe load does not de-
crease working memory performance measured at each
of the four time points (T1 to T4) using accuracy in the
visual n-back task of the TAP [37].
Secondary outcomes
The study further aims to assess the influence of a 4-
week period of Phe load on working memory perform-
ance (reaction time, visual n-back task, TAP [37]), inhib-
ition (third condition, Color-Word Interference Test, D-
KEFS [39]), cognitive flexibility (fourth condition, Color-
Word Interference Test, D-KEFS [39]), intensity of
neural activation during the working memory task in the
MR scanner (n-back task fMRI), strength of functional
connectivity between brain regions related to working
memory (resting-state fMRI), and on brain Phe concen-
trations (MRS). All secondary outcomes will be assessed
at all four time points (T1 to T4).
Other outcomes
The PICO Study will further investigate the influence of a
4-week period of Phe load on cognitive performance, spe-
cifically on sustained and divided attention, fine motor
control, verbal and design fluency, processing speed, mood
(short form of the Profile of Mood States, POMS [41];
Beck’s Depression Inventory, BDI-II [42]) and health-
related quality of life (PKU quality of life, PKUQOL [43]).
Additionally, the influence of temporarily elevated Phe
concentrations on integrity of white matter tracts (DTI)
and cerebral blood flow (ASL) will be investigated.
Moreover, the study assesses differences between pa-
tients with early-treated PKU and healthy controls in re-
gard to cognitive variables, intensity of neural activation
during the working memory task, strength of connectiv-
ity between brain regions involved in working memory,
and structural brain characteristics.
Statistical analysis
The calculation of the sample size is based on the pri-
mary outcome (accuracy, visual n-back task of the TAP)
for the intra-individual comparison within the different
groups using a crossover design. The power analysis was
done using Stata based on a paired means test. A nonin-
feriority margin of 4% in working memory (n-back task)
is regarded as clinically irrelevant. This margin is based
on a study with healthy adults presenting a standard de-
viation of 4% in the accuracy condition of the n-back
task [46]. Hence, a performance change in the n-back
task of 4% or less would support our noninferiority hy-
pothesis. According to Zimmermann and Fimm (2009),
the test-retest reliability of the n-back task is 0.67 [37].
The correlation between two periods will be lower.
Therefore, a correlation of 0.5 was assumed for this sam-
ple size calculation. Based on reported standard devia-
tions in a n-back task in patients with PKU ranging from
5% to 8% (off-diet: SD = 7.6; on-diet: SD = 5.7 [27]), a
standard deviation of 8% is expected (assuming that pa-
tients are off-diet during the 4 weeks Phe treatment).
Based on these assumptions, the PICO Study will be able
to detect noninferiority at a margin of 4%, a power of
80%, and a one-sided alpha level of 0.05, with a sample
size of 26 patients. From earlier studies, including pa-
tients with PKU in Bern [47], patients with PKU are
known to be highly motivated. Still, we might need to
compensate for possible dropouts, which are suggested
to fall between approximately 18% and 30% in other
studies including patients with PKU [24, 28]; therefore,
the goal has been set to 30 patients. Additionally, the ef-
fect size that would be detectable at different sample
sizes and correlations for the comparison of the healthy
control group and the experimental group (assuming the
same number of controls and patients) was assessed.
With a sample size of twice 26 participants and a power
of 80%, an effect size of 0.79 could be detected at a two-
sided alpha level of 0.05. To match the number of pa-
tients, the goal has been set to 30 controls.
Data will be analyzed according to the intention-to-
treat (ITT) principle whereby all randomized partici-
pants will be analyzed in the randomized group regard-
less of any protocol violations. Moreover, data will be
analyzed in the per-protocol patient set, excluding pa-
tients who did not receive the randomized treatment
schedule, patients who did not comply with the inter-
vention (i.e., unable to follow all four time points, unable
to adhere to the treatment arms), or patients who vio-
lated major eligibility criteria (i.e., onset of a pregnancy,
onset of a concomitant disease status that could affect
primary or secondary outcome).
The primary analysis will be performed in the random-
ized patient group. As recommended by the CONSORT
statement for noninferiority trials [48], the analysis of the
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primary outcome will be based on the ITT as well as per-
protocol patient set. Raw data of the n-back task will be
transformed into standardized values using age matched
normative data from the test manual. Normality of data
will be assessed via graphical representation of data. Lin-
ear mixed effects models will be used to calculate the
lower one-sided 95% confidence limit of the primary out-
come. If the lower limit lies above the noninferiority mar-
gin of 4% in both analysis sets, noninferiority will be
claimed. The mixed effects model will contain the baseline
measurements, the 4 weeks measurements, and an indica-
tor for the treatment and period as fixed effects, and a ran-
dom effect for participants. All primary and secondary
continuous endpoints will be analyzed via this approach.
Secondary outcomes will primarily be analyzed in the ITT
patient set. Secondary outcomes will additionally be evalu-
ated in the per-protocol patient set. Furthermore, proc-
essed neuroimaging data will be compared in a cross-
sectional and longitudinal manner. Due to the expected
heterogeneity of the patient sample, comparisons will be
focused on intra-individual changes of cerebral metabol-
ism and functional integrity (comparison Phe vs placebo).
Differences between groups will be investigated by linear
mixed models, as described above. For the comparison of
baseline values between patients and controls, regular lin-
ear regression models adjusted for potential confounders
will be used.
One interim analysis is planned for the reassessment
of the sample size. Currently no reliable data are avail-
able on the correlation between the baseline and 4-
weeks measurement and between the two different treat-
ment periods for the n-back test. Therefore, the sample
size will be re-assessed after 50% of patients to assure
sufficient power. The re-assessment of the sample size
will only be based on the observed standard deviations
and correlations between baseline and follow-up values
and between treatment periods. Observed changes
within and between treatment periods will not be dis-
played, nor will the noninferiority margin be modified.
No formal testing will take place; therefore, the alpha-
level does not require adjustment.
Simple descriptive statistics will be used for evaluation
of questionnaires on adverse events and mood. No for-
mal statistical testing will be performed.
Data management
The case report forms (CRFs) in this trial are imple-
mented electronically using a dedicated electronic data
capturing (EDC) system (REDCap™, https://www.project-
redcap.org/). The EDC system is activated for the trial
only after successfully passing a formal test procedure. All
data entered in the CRFs are stored on a Linux server in a
dedicated mySQL database. Responsibility for hosting the
EDC system and the database lies with CTU Bern.
Monitoring
On-site as well as central data monitoring will be part of
the quality control activities implemented for this study.
Monitoring will be performed according to a separate
monitoring plan in collaboration with CTU Bern.
Discussion
The PICO Study will help provide some much-needed
answers on whether a rigorous protein-restricted diet to
control Phe-levels is indispensable for adults with early-
treated PKU. Using a combination of neuropsychological
and neuroimaging data, the PICO Study will consider-
ably contribute to an improvement of the currently in-
sufficient level of evidence on how adult patients with
early-treated PKU should be managed.
The double-blind, placebo-controlled design will elim-
inate the expectation bias of patients and physicians
otherwise inherent to dietary interventions. Potentially
positive effects of the recommended dietary restrictions
have to be proven by means of double-blinded interven-
tion trials and not only deduced from biased open inter-
ventions and association studies. This determination is
particularly important in light of the potential risks of a
lifelong low-protein diet. Similar to a strict vegan diet, a
Phe-restricted diet not only lacks proteins but also many
micronutrients, both of which have to be monitored and
compensated with supplements [49]. In addition, the re-
strictive diets may be associated with a predisposition or
aggravation of psychiatric problems by itself: eating dis-
orders and obsessive compulsive disorder are four times
more common in patients with PKU compared to the
general population and twice as common as in patients
with diabetes mellitus [50].
During the intervention phase, transient mild cognitive
impairments might occur due to an increased Phe load. A
similar smaller study with increased Phe load over 4 weeks
suggested an impairment in sustained attention as well as
lower scores in mood profile but did not report any other
mild or serious adverse events [28]. Serious side effects are
not to be expected. Neither is hyperphenylalaninemia in
adulthood known as a cause of metabolic encephalopathy,
nor is there a recognized acute decompensation of PKU
[51]. The probability of irreversible adverse events during
the progress of the present study is therefore extremely
low. Even in adult patients with PKU not following any
low protein diet for a long time, only very few cases of ser-
ious neurologic events with unlikely causal relationship
(some of them probably caused by severe vitamin B12 defi-
ciency) have been described in the literature: 11 cases of
spastic paraparesis, three cases of muscle weakness/diffi-
culty walking, and three cases of vision loss [52]. Despite
not following any low protein diet for a long time, most
adult patients showed improved scores for attention as well
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as self-reported anxiety and depression after reintroducing
a low-protein diet [21, 53].
Neuroimaging has become an indispensable tool to
better understand brain regions of susceptibility in
metabolic disease and to assess the efficacy of dietary
treatment on the brain. Clinicians can benefit from
the technologic advancements in neuroimaging, allow-
ing for improved understanding of diseases and ame-
liorated patient management. Only a limited number
of neuroimaging studies have been conducted so far
in patients with PKU. This is evident on a cross-
sectional level but even more so on a longitudinal
level. Hence, conclusive evidence on the influence of
Phe on brain structure and function is not available
with the current state of knowledge. By combining a
broad range of advanced MR-techniques, the PICO
Study strives to advance our understanding of the dis-
ease PKU and its impact on different properties of
the brain. The additional information gained by the
neuroimaging results may help to characterize sub-
groups of patients that benefit or do not benefit from
restrictive dietary interventions.
Evaluation of patients’ perceived cognitive performance
is an important part of routine patient care [29]. However,
patients’ reports may be prone to a substantial expectation
bias as they are usually aware of their recent compliance
with dietary restrictions. This double-blinded trial offers a
unique opportunity to evaluate the reliability of self-
assessment of adult patients with early-treated PKU.
The PICO Study also yields an economical point of
view. Phe-restricted diet, including the use of amino acid
supplements and low-protein medical foods, costs ap-
proximately 20,000 CHF or USD per year, and patient.
Sapropterin (Kuvan®), which can be used in a small sub-
set of patients with BH4-responsive PKU, costs approxi-
mately 180,000 CHF or USD annually. Also pegvaliase
(Palynziq®), the new enzyme substitution therapy [54–
56], is estimated to cost approximately 190,000 CHF or
USD per year and patient. Of note, neither sapropterin
nor pegvaliase enabled clinically relevant significant im-
provement of cognitive outcome [22, 24, 57, 58].
Two limitations of the study inherent to the design
need to be mentioned. First, being “off-diet” is mim-
icked, not conducted. Second, the duration of the
intervention does not reflect an indefinite discontinu-
ation of the Phe-restricted diet, and long-term effects
of elevated Phe levels still remain largely unknown.
The oldest early-treated patients with PKU are now
only in their early 50s. This is a strong argument for
keeping all patients with PKU under periodic review
and making sure that even those who have stopped
dietary treatment are not lost to follow-up. Carefully
conducted long-term cohort studies are needed to
learn more about the course of the disease as patients
age. Based on the current state-of-the-art, patients
and their metabolic specialists are unlikely to agree to
a longer intervention. A confirmation of the hypothe-
sized noninferiority of Phe could justify a larger long-
term trial and support the willingness of patients and
treating metabolic specialists to participate in such a
long-term clinical trial.
In summary, this double-blinded, randomized, placebo-
controlled, crossover, noninferiority trial using a combin-
ation of cognitive and neuroimaging data, will consider-
ably contribute to improve the currently insufficient level
of evidence on how adult patients with early-treated PKU
should be managed.
Trial status
The study was reviewed by the Clinical Trial Unit in
Bern and was approved by the ethics committee of the
canton of Bern, Switzerland, in December 2018 (2018–
01609). The manuscript includes all revisions. Recruit-
ment will start in July 2019 and will end in June 2021.
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